Decreased binding of the D 3 dopamine receptor-preferring ligand [ 11 C]-(+)-PHNO in drug-naïve Parkinson's disease

Author： Boileau Isabelle  

Publisher： Oxford University Press

ISSN： 1460-2156

Source： Brain, Vol.132, Iss.5, 2009-05, pp. : 1366-1375

Disclaimer: Any content in publications that violate the sovereignty, the constitution or regulations of the PRC is not accepted or approved by CNPIEC.

Previous Menu Next

Abstract

Related content

Dopamine D 3 receptor agents as potential new medications for drug addiction

By Le Foll B.   Schwartz J.C.   Sokoloff P.  

European Psychiatry, Vol. 15, Iss. 2, 2000-03 ,pp. : 140-146

Elsevier

Access to resources Recommend Favorite

Dopamine receptor agonists in the therapy of Parkinson’s disease

By Foley P.   Gerlach M.   Double K. L.   Riederer P.  

Journal of Neural Transmission, Vol. 111, Iss. 10-11, 2004-10 ,pp. : 1375-1446

Springer Publishing Company

Access to resources Recommend Favorite

Pharmacological treatment of Parkinson's disease: life beyond dopamine D2/D3 receptors?

By Linazasoro G.  

Journal of Neural Transmission, Vol. 115, Iss. 3, 2008-03 ,pp. : 431-441

Springer Publishing Company

Access to resources Recommend Favorite

Error Analysis for Quantification of [11C]FLB 457 Binding to Extrastriatal D2 Dopamine Receptors in the Human Brain

By Ito H.   Sudo Y.   Suhara T.   Okubo Y.   Halldin C.   Farde L.  

NeuroImage, Vol. 13, Iss. 3, 2001-03 ,pp. : 531-539

Academic Press

Access to resources Recommend Favorite

Oligomers of D2 dopamine receptors: Evidence from ligand binding

By Strange Philip  

Journal of Molecular Neuroscience, Vol. 26, Iss. 2-3, 2005-06 ,pp. : 155-160

Humana Press, Inc

Access to resources Recommend Favorite